---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-086903"
form_type: "8-K"
ticker: "ELAN"
cik: "0001739104"
company_name: "Elanco Animal Health Inc"
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:54:58.361394+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elanco Q2 revenue $1.177B down 8%; cuts full-year guidance on macro headwinds

## Summary
- Q2 revenue $1,177M (-8% reported, -4% constant currency); Pet Health $612M (-11%), Farm Animal $553M (-2%).
- Reported EPS $(0.04), adjusted EPS $0.36; adjusted EBITDA $300M (25.5% margin) vs $291M prior year.
- Full-year revenue guidance cut to $4,465-$4,550M from $4,700-$4,755M; adjusted EPS now $1.06-$1.13 vs $1.15-$1.21.
- Net leverage 5.3x; target ~5.0x by year-end; 60% gross margin and 31% adjusted EBITDA timeline extended.
- In-licensed feline diabetes product under FDA review; Zorbium launched; pipeline on track for two blockbuster submissions.

## SEC filing metadata
- accession: 0001104659-22-086903
- form_type: 8-K
- ticker: ELAN
- cik: 0001739104
- company_name: Elanco Animal Health Inc
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739104/000110465922086903/0001104659-22-086903-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739104/000110465922086903/tm2222756d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-086903
- JSON: https://secwatch.observer/filing/0001104659-22-086903.json
- Plain text: https://secwatch.observer/filing/0001104659-22-086903.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.